Total Payments
$71,072
2024 Payments
$9,636
Companies
14
Transactions
52
Medicare Patients
270
Medicare Billing
$40,985
Payment Breakdown by Category
Consulting$61,977 (87.2%)
Research$3,773 (5.3%)
Travel$3,177 (4.5%)
Other$1,350 (1.9%)
Food & Beverage$781.76 (1.1%)
Education$13.62 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $61,977 | 30 | 87.2% |
| Unspecified | $3,773 | 4 | 5.3% |
| Travel and Lodging | $3,177 | 4 | 4.5% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $1,000 | 1 | 1.4% |
| Food and Beverage | $781.76 | 10 | 1.1% |
| Grant | $350.00 | 1 | 0.5% |
| Education | $13.62 | 2 | 0.0% |
Payments by Type
General
$67,299
48 transactions
Research
$3,773
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca UK Limited | $20,150 | 12 | $0 (2024) |
| Clovis Oncology, Inc. | $14,650 | 5 | $0 (2022) |
| GlaxoSmithKline, LLC. | $8,000 | 5 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $6,944 | 10 | $0 (2017) |
| TESARO, Inc. | $6,447 | 7 | $0 (2018) |
| ABBVIE INC. | $4,530 | 3 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $3,173 | 2 | $0 (2019) |
| PUMA BIOTECHNOLOGY, INC. | $2,560 | 1 | $0 (2024) |
| PFIZER INC. | $2,520 | 1 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $1,000 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,636 | 8 | ABBVIE INC. ($4,530) |
| 2023 | $5,921 | 5 | AstraZeneca UK Limited ($3,000) |
| 2022 | $6,950 | 5 | AstraZeneca UK Limited ($4,000) |
| 2021 | $12,500 | 7 | AstraZeneca UK Limited ($7,000) |
| 2020 | $10,700 | 4 | Clovis Oncology, Inc. ($7,700) |
| 2019 | $11,973 | 6 | Clovis Oncology, Inc. ($5,300) |
| 2018 | $108.64 | 1 | TESARO, Inc. ($108.64) |
| 2017 | $13,283 | 16 | Teva Pharmaceuticals USA, Inc. ($6,944) |
All Payment Transactions
52 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/29/2024 | ABBVIE INC. | ELAHERE (Drug) | Consulting Fee | Cash or cash equivalent | $4,400.00 | General |
| Category: ONCOLOGY | ||||||
| 09/20/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $102.23 | General |
| Category: ONCOLOGY | ||||||
| 08/16/2024 | PUMA BIOTECHNOLOGY, INC. | — | Consulting Fee | Cash or cash equivalent | $2,560.00 | General |
| 06/11/2024 | AstraZeneca UK Limited | LYNPARZA (Drug) | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| Category: Oncology | ||||||
| 06/02/2024 | AstraZeneca Pharmaceuticals LP | — | Grant | Cash or cash equivalent | $350.00 | General |
| 06/02/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $46.49 | General |
| 06/02/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $27.35 | General |
| Category: ONCOLOGY | ||||||
| 02/14/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 11/07/2023 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $2,520.00 | General |
| 06/29/2023 | AstraZeneca UK Limited | LYNPARZA (Drug) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: Oncology | ||||||
| 03/16/2023 | AstraZeneca UK Limited | LYNPARZA (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Oncology | ||||||
| 02/23/2023 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $101.35 | General |
| Category: Oncology | ||||||
| 01/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $300.00 | Research |
| Study: A PHASE 1A/1B STUDY OF LY3484356 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH ABEMACICLIB TO PATIENTS WITH ER+ HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER | ||||||
| 10/28/2022 | Clovis Oncology, Inc. | Rubraca (Drug) | Consulting Fee | Cash or cash equivalent | $1,650.00 | General |
| Category: Oncology | ||||||
| 06/24/2022 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 05/10/2022 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $300.00 | Research |
| Study: A PHASE 1A/1B STUDY OF LY3484356 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH ABEMACICLIB TO PATIENTS WITH ER+, HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER | ||||||
| 03/04/2022 | AstraZeneca UK Limited | LYNPARZA (Drug) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: Oncology | ||||||
| 11/16/2021 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 07/13/2021 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 02/24/2021 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 02/22/2021 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 02/22/2021 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 02/05/2021 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 01/12/2021 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AN OPEN-LABEL, RANDOMIZED, PHASE 3 CLINICAL TRIAL OF REGN2810 VERSUS THERAPY OF INVESTIGATOR'S CHOICE CHEMOTHERAPY IN RECURRENT OR METASTATIC PLATINUM-REFRACTORY CERVICAL CARCINOMA | Regeneron Pharmaceuticals, Inc. | $3,173 | 2 |
| A PHASE 1A/1B STUDY OF LY3484356 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH ABEMACICLIB TO PATIENTS WITH ER+ HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER | Eli Lilly and Company | $300.00 | 1 |
| A PHASE 1A/1B STUDY OF LY3484356 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH ABEMACICLIB TO PATIENTS WITH ER+, HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER | Eli Lilly and Company | $300.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 72 | 160 | $50,016 | $12,716 |
| 2022 | 2 | 70 | 139 | $38,892 | $8,826 |
| 2021 | 3 | 82 | 156 | $45,949 | $11,676 |
| 2020 | 2 | 46 | 113 | $31,537 | $7,767 |
Total Patients
270
Total Services
568
Medicare Billing
$40,985
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 27 | 76 | $23,442 | $5,944 | 25.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 16 | 29 | $10,873 | $3,337 | 30.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 12 | 27 | $8,181 | $2,037 | 24.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 17 | 28 | $7,520 | $1,398 | 18.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 21 | 36 | $10,908 | $2,818 | 25.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 22 | 52 | $13,520 | $2,767 | 20.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 11 | 28 | $8,484 | $2,092 | 24.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 16 | 23 | $5,980 | $1,150 | 19.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 13 | 38 | $11,514 | $3,137 | 27.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 17 | 42 | $10,920 | $2,263 | 20.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 12 | 15 | $5,595 | $1,823 | 32.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 18 | 31 | $8,060 | $1,565 | 19.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 11 | 19 | $5,757 | $1,521 | 26.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 11 | 11 | $4,103 | $1,367 | 33.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 18 | 49 | $13,041 | $3,116 | 23.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 15 | 42 | $12,210 | $2,712 | 22.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 13 | 22 | $6,286 | $1,940 | 30.9% |
About Dr. Don Dizon, MD
Dr. Don Dizon, MD is a Medical Oncology healthcare provider based in Providence, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1376573394.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Don Dizon, MD has received a total of $71,072 in payments from pharmaceutical and medical device companies, with $9,636 received in 2024. These payments were reported across 52 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($61,977).
As a Medicare-enrolled provider, Dizon has provided services to 270 Medicare beneficiaries, totaling 568 services with total Medicare billing of $40,985. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Providence, RI
- Active Since 07/04/2006
- Last Updated 12/02/2019
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1376573394
Products in Payments
- Rubraca (Drug) $14,650
- LYNPARZA (Drug) $11,150
- ELAHERE (Drug) $4,530
- LIBTAYO (Biological) $3,173
- ZEJULA (Drug) $122.26
- Orserdu (Drug) $101.35
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Providence
Dr. Mohammed Jaloudi, Md, MD
Medical Oncology — Payments: $86,431
Medical Oncology $86,431
Dr. Benedito Carneiro, Md, MD
Medical Oncology — Payments: $24,852
Medical Oncology $24,852
Dr. Susan Gingrich, Md, MD
Medical Oncology — Payments: $1,897
Medical Oncology $1,897
Rochelle Strenger, Md, MD
Medical Oncology — Payments: $125.33
Medical Oncology $125.33
Dr. Kathryn Decarli, M.d, M.D
Medical Oncology — Payments: $124.80
Medical Oncology $124.80
Dr. Medhavi Gupta, M.d, M.D
Medical Oncology
Medical Oncology